<DOC>
	<DOCNO>NCT02265237</DOCNO>
	<brief_summary>The purpose study HCV genotype 4-infected subject compensate cirrhosis ass safety compare percentage subject achieve 12-week sustained virologic response ( SVR12 ) , [ HCV ribonucleic acid ( RNA ) &lt; low limit quantification ( LLOQ ) 12 week follow treatment ] , clinically relevant threshold [ base SVR rate HCV genotype 4-infected subject treat pegylated interferon ( pegIFN ) /RBV ] . The 12 16-week arm fully enrol . As 19 May 2015 , close two 24-week arm open enrollment .</brief_summary>
	<brief_title>A Randomized , Open-Label Study Evaluate Safety Efficacy Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin ( RBV ) Adults With Genotype 4 Chronic Hepatitis C Virus ( HCV ) Infection Cirrhosis ( AGATE-1 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Subjects must meet one follow : Treatmentnaive ( Subject never receive antiviral treatment hepatitis C infection ) OR For Arms A , B , C : Treatment Experienced ( Prior null responder , Partial responder Relapsers IFN/RBV ) For Arm D : Treatment Experienced ( Prior sofosbuvir ( SOF ) breakthrough/nonresponder Prior SOF relapser SOF/pegIFN/RBV SOF/RBV ) Subject plasma HCV RNA &gt; 1000 IU/mL Screening Chronic HCV genotype 4 infection cirrhosis Positive test result Screening Hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) . Current enrollment another interventional clinical study , previous enrollment study , previous use protease inhibitor , nonnucleoside polymerase inhibitor , Nonstructural viral protein ( NS ) 5A inhibitor , either investigational commercially available ( include previous exposure ABT450 ombitasvir ) , receipt investigational product within 6 week prior study drug administration . Prior use directacting antiviral allow , except Arm D prior experience nucleoside polymerase inhibitor , sofosbuvir pegIFN/RBV SOF RBV require . Any current past clinical evidence ChildPugh B C classification clinical history liver decompensation include ascites , variceal bleeding , hepatic encephalopathy . Confirmed presence hepatocellular carcinoma . Any cause liver disease chronic HCV infection . Abnormal laboratory test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C Genotype 4</keyword>
	<keyword>Chronic Hepatitis C</keyword>
</DOC>